Nanjing, May 20, 2025 — GenScript Biotech Corporation (“GenScript”) today announced a strategic partnership with Bioelectronica Holdings Inc. The two companies will integrate Bioelectronica’s globally leading single B cell high-throughput screening technology with GenScript’s end-to-end antibody development service platform to jointly launch a comprehensive antibody discovery solution. This collaboration aims to help global biopharma companies break through R&D efficiency bottlenecks and achieve cost-effective innovation.

​

Technology Upgrade: Single B Cell Platform + AI Algorithms to Accelerate Efficient Antibody Development

At the core of this collaboration is Bioelectronica’s self-developed Hypercell high-throughput single-cell screening system, which incorporates the AI-powered antibody sequence prediction software AbFinderAI. This system enables precise selection of high-quality antibody sequences from single B cells, significantly improving the efficiency of candidate antibody screening. Leveraging GenScript’s mature platforms in gene synthesis, protein expression, and antibody engineering, the collaboration will accelerate candidate validation and the rapid transition from discovery to clinical development.

​

As part of the partnership, GenScript has officially adopted the Hypercell system and integrated it into its existing antibody development services. Through this technical synergy, the traditional clone validation cycle in antibody screening workflows can be shortened by more than 50%, while reducing costs from redundant experiments—providing more cost-effective R&D support to customers.

 

Collaborative Value: Full-Chain Capability Integration

This partnership integrates the strengths of both companies to deliver more efficient solutions for antibody drug development.

​

• From a technical perspective, Bioelectronica’s single B cell technology enhances antibody discovery efficiency, while GenScript’s large-scale manufacturing and CRDMO capabilities ensure rapid implementation of technology outcomes—creating a highly complementary partnership.​

 

• From a workflow perspective, both systems are deeply integrated. Customers can access GenScript’s services in gene synthesis and protein expression directly through Bioelectronica’s AbFinderAI platform, enabling seamless data flow and process automation for enhanced efficiency.

​

• From a cost perspective, this one-stop solution helps global customers reduce R&D barriers by streamlining the entire discovery-to-delivery process.

​​

Future Outlook: Five-Year Strategic Alignment to Build Industry Ecosystem

Over the next five years, the two companies plan to deepen their collaboration across the following key areas:

​

1.       Standardized Workflow Development

         Co-developing standardized full-process service protocols for single B cell antibody discovery to drive scalable deployment of the technology.

2.       Technology Innovation Expansion

        The partnership will extend beyond current offerings to explore cutting-edge areas such as iterative AI algorithm development and cell therapy applications—further strengthening competitive service capabilities.

3.       Global Market Expansion

         Leveraging GenScript’s global R&D centers and manufacturing sites, the partnership aims to rapidly bring the technology to the U.S., Europe, and emerging markets, offering efficient services to a broader customer base.

About Bioelectronica 

​

Bioelectronica focuses on the development of single-cell and single-microbe technologies. Its Hypercell high-throughput screening system, combined with AI algorithms, is widely used in antibody discovery, immunology research, and precision medicine—delivering efficient and accurate technical support to customers around the world.